Restylane Defyne Lidocaine 1ml — OBT Technology Filler for Deep Folds & Chin Augmentation

Restylane Defyne Lidocaine 1ml is a hyaluronic acid dermal filler manufactured by Galderma using their proprietary OBT / XpresHAn Technology. It contains 20 mg/mL of cross-linked HA and 3 mg/mL (0.3%) lidocaine. The product is FDA-approved for two indications: correction of moderate-to-severe deep facial wrinkles and folds (such as nasolabial folds and marionette lines), and augmentation of the chin region for mild-to-moderate chin retrusion in patients over 21.

OBT stands for Optimal Balance Technology, globally branded as XpresHAn Technology by Galderma. It is a monophasic cross-linking process that produces a smooth, integrative gel with calibrated flexibility. Unlike NASHA technology (used in Restylane classic and Restylane LYFT) which prioritises firm projection, OBT prioritises movement and natural expression — making it especially suited to dynamic facial zones like the lower face.

Both Defyne and Refyne use the same OBT / XpresHAn Technology, the same 20 mg/mL HA concentration, and the same 0.3% lidocaine. The difference is cross-linking density and firmness: Defyne is firmer with higher lifting capacity for deep nasolabial folds, marionette lines, and chin augmentation; Refyne is softer with greater flexibility for moderate folds in highly dynamic zones. A patient with deep nose-to-mouth lines typically receives Defyne; moderate folds with strong facial expression typically receive Refyne.

Yes. In January 2021, the FDA approved Restylane Defyne for the augmentation and correction of mild-to-moderate chin retrusion in adults over 21 — making it the first and only XpresHAn / OBT technology filler with US chin augmentation approval. Clinical study data showed 86.1% of patients achieved improved chin profile appearance at 12 weeks post-treatment.

Per the manufacturer’s clinical data, Restylane Defyne delivers up to 12 months of correction in facial wrinkles and folds, and similar durability for chin augmentation. In a randomized controlled study for nasolabial folds, 69.8% of subjects maintained clinically significant improvement at 48 weeks. Individual duration depends on dose, placement depth, patient metabolism, and facial movement intensity.

Restylane Defyne is manufactured by Q-Med AB, a Galderma subsidiary based in Uppsala, Sweden. Galderma is one of the world’s largest independent dermatology companies, headquartered in Lausanne, Switzerland. The Restylane brand has over 25 years of clinical history and more than 40 million treatments performed globally.

Per the Galderma Instructions for Use, Restylane Defyne is intended for injection into the mid-to-deep dermis for nasolabial fold correction. For chin augmentation, the product is placed in the subcutaneous and/or supraperiosteal layer of the chin region. The standard supplied needles are 27G 1/2 inch ultra-thin wall; some practitioners prefer a 27G blunt cannula for deeper placements.

Yes — combining Restylane products in a single full-face protocol is standard Galderma-recommended practice. A typical layered protocol might use Restylane Lyft for cheek volume, Restylane Defyne for nasolabial folds and chin, Restylane Refyne for moderate marionette lines, and Restylane Kysse for lip augmentation. All Restylane products share the same 20 mg/mL HA base concentration and have established compatibility data.

Store Restylane Defyne in its original packaging at 2-25 °C, away from direct sunlight. Do not freeze. Shelf life is typically 24 months from manufacturing date when unopened. Once a syringe is opened, contents must be used immediately — the product is single-use sterile and partial syringes cannot be retained.

No. Restylane Defyne uses non-animal stabilized hyaluronic acid (NASHA precursor technology) produced by bacterial fermentation. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins, but contains no animal proteins or by-products.